Protagonist Therapeutics Total Assets 2015-2022 | PTGX
Protagonist Therapeutics total assets from 2015 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Protagonist Therapeutics Annual Total Assets
(Millions of US $) |
| 2022 |
$248 |
| 2021 |
$348 |
| 2020 |
$324 |
| 2019 |
$155 |
| 2018 |
$139 |
| 2017 |
$164 |
| 2016 |
$94 |
| 2015 |
$15 |
| 2014 |
$10 |
Protagonist Therapeutics Quarterly Total Assets
(Millions of US $) |
| 2022-12-31 |
$248 |
| 2022-09-30 |
$282 |
| 2022-06-30 |
$311 |
| 2022-03-31 |
$348 |
| 2021-12-31 |
$348 |
| 2021-09-30 |
$373 |
| 2021-06-30 |
$404 |
| 2021-03-31 |
$298 |
| 2020-12-31 |
$324 |
| 2020-09-30 |
$217 |
| 2020-06-30 |
$225 |
| 2020-03-31 |
$135 |
| 2019-12-31 |
$155 |
| 2019-09-30 |
$155 |
| 2019-06-30 |
$148 |
| 2019-03-31 |
$132 |
| 2018-12-31 |
$139 |
| 2018-09-30 |
$149 |
| 2018-06-30 |
$137 |
| 2018-03-31 |
$149 |
| 2017-12-31 |
$164 |
| 2017-09-30 |
$110 |
| 2017-06-30 |
$70 |
| 2017-03-31 |
$83 |
| 2016-12-31 |
$94 |
| 2016-09-30 |
$103 |
| 2016-06-30 |
$25 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2014-12-31 |
$10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.078B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
